Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment
Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafami...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9d3ffc1208904aa28931aba01e50d1aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9d3ffc1208904aa28931aba01e50d1aa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9d3ffc1208904aa28931aba01e50d1aa2021-11-11T17:31:45ZPrognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment10.3390/jcm102148682077-0383https://doaj.org/article/9d3ffc1208904aa28931aba01e50d1aa2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4868https://doaj.org/toc/2077-0383Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98]; <i>p</i> = 0.032). In Cohort A, baseline NT-proBNP > 3000 ng/L and cTnT-HS > 50 ng/L and a relative increase of NT-proBNP > 50% during follow-up were independent prognostic factors of EFS. The slopes of logs NT-proBNP and cTnT-HS increased with time before and stabilized after tafamidis. Conclusion: ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis.Silvia OghinaConstant JosseMélanie BézardMounira KharoubiMarc-Antoine DelbarreDamien EyhartsAmira ZarouiSoulef GuendouzArnault GalatLuc HittingerPascale FanenEmmanuel TeigerNadir MouriFrançois MontestrucThibaud DamyMDPI AGarticleheart failurecardiac amyloidosistransthyretinbiomarkersprognosistreatmentMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4868, p 4868 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
heart failure cardiac amyloidosis transthyretin biomarkers prognosis treatment Medicine R |
| spellingShingle |
heart failure cardiac amyloidosis transthyretin biomarkers prognosis treatment Medicine R Silvia Oghina Constant Josse Mélanie Bézard Mounira Kharoubi Marc-Antoine Delbarre Damien Eyharts Amira Zaroui Soulef Guendouz Arnault Galat Luc Hittinger Pascale Fanen Emmanuel Teiger Nadir Mouri François Montestruc Thibaud Damy Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| description |
Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafamidis (Cohort A) and 248 ATTR-CA with tafamidis (Cohort B) were enrolled. Event-free survival (EFS) events were death, heart transplant, or acute heart failure. In Cohort A, 27% of patients maintained NT-proBNP < 3000 ng/L and 14% cTnT-HS < 50 ng/L at 12 months relative to baseline levels. In Cohort B, the proportions were 49% and 29%, respectively. In Cohort A, among the 333 patients without an increased NT-proBNP > 50% relative to baseline EFS was extended compared to the 121 patients with an increased NT-proBNP > 50% (HR: 0.75 [0.57; 0.98]; <i>p</i> = 0.032). In Cohort A, baseline NT-proBNP > 3000 ng/L and cTnT-HS > 50 ng/L and a relative increase of NT-proBNP > 50% during follow-up were independent prognostic factors of EFS. The slopes of logs NT-proBNP and cTnT-HS increased with time before and stabilized after tafamidis. Conclusion: ATTR-CA patients with increasing NT-proBNP had an increased risk of EFS. Tafamidis stabilize NT-proBNP and cTnT-HS increasing, even if initial NT-proBNP levels were >3000 ng/L. Thus suggesting that all patients, irrespective of baseline NT-proBNP levels, may benefit from tafamidis. |
| format |
article |
| author |
Silvia Oghina Constant Josse Mélanie Bézard Mounira Kharoubi Marc-Antoine Delbarre Damien Eyharts Amira Zaroui Soulef Guendouz Arnault Galat Luc Hittinger Pascale Fanen Emmanuel Teiger Nadir Mouri François Montestruc Thibaud Damy |
| author_facet |
Silvia Oghina Constant Josse Mélanie Bézard Mounira Kharoubi Marc-Antoine Delbarre Damien Eyharts Amira Zaroui Soulef Guendouz Arnault Galat Luc Hittinger Pascale Fanen Emmanuel Teiger Nadir Mouri François Montestruc Thibaud Damy |
| author_sort |
Silvia Oghina |
| title |
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| title_short |
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| title_full |
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| title_fullStr |
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| title_full_unstemmed |
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment |
| title_sort |
prognostic value of n-terminal pro-brain natriuretic peptide and high-sensitivity troponin t levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/9d3ffc1208904aa28931aba01e50d1aa |
| work_keys_str_mv |
AT silviaoghina prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT constantjosse prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT melaniebezard prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT mounirakharoubi prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT marcantoinedelbarre prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT damieneyharts prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT amirazaroui prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT soulefguendouz prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT arnaultgalat prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT luchittinger prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT pascalefanen prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT emmanuelteiger prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT nadirmouri prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT francoismontestruc prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment AT thibauddamy prognosticvalueofnterminalprobrainnatriureticpeptideandhighsensitivitytroponintlevelsinthenaturalhistoryoftransthyretinamyloidcardiomyopathyandtheirevolutionaftertafamidistreatment |
| _version_ |
1718432079036809216 |